Tweetovi
- Tweetovi, trenutna stranica.
- Tweetovi i odgovori
- Medijski sadržaj
Blokirali ste korisnika/cu @LeukDocJZ
Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @LeukDocJZ
-
Fascinating paper by
@DanPollyea and colleagues in@CD_AACR showing that monocytic phenotypes (ie M5) do not respond well to Venetoclax due to low BCL-2 & MCL-1 dependence. Targeting MCL-1 (directly or indirectly) represents a rational approach after Tx w/Ven (esp M5).#leusmhttps://twitter.com/DanPollyea/status/1220513641553973249 …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Grateful for our amazing Leukemia Research Team! Without your critical support, we would not be able to conduct cutting edge clinical trials and strive to find cures for leukemia(s)! Thanks for all that you do!
@UNC_Lineberger@calliecoombsmd@blairbear43@angienicholsNPpic.twitter.com/dyQZq0ISTw
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
My intern arrives to rounds today with APL sneakers...and I can even detect an Auer rod through the name! Bad omen for the Leukemia service? I told him to differentiate his sneakers to a different brand!
#leusmpic.twitter.com/JKqXF4U4Zt
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Joshua Zeidner proslijedio/la je Tweet
#UNC Lineberger's Christopher Dittus, DO, MPH, is the editor of a new book that provides a comprehensive review of how to diagnose and manage rare lymphomas.http://go.unc.edu/rare-lymphomas-book …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Grateful for the support of
@NCICTEP_ClinRes, mentorship from Dr. Ivana Gojo@hopkinskimmel, translational correlates spearheaded by Dr. Hanna Knaus and Dr. Leo Luznik. Great collaboration with Dr. Amer Zeidan@YaleCancer,@calliecoombsmd@AmyDeZern@Dr_BDSmithPrikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
8/ Ultimately, we hope these findings will provide a springboard for the next generation of clinical trials with Pomalidomide & other immune modulatory strategies at early recovery post-induction chemo in AML to improve clinical outcomes.
Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
7/ Pomalidomide led to significant decrease in Aiolos and impacted T cell differentiation and activation, supporting our translational hypothesis. Moreover, Pom decreased suppressive Treg gene signatures while activating cell cycle pathways in T cell subpopulations.
Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
6/ Although small #'s, we saw clinical activity with the addition of pomalidomide- overall 75% CR and 77% CR/CRi among those Tx with Pom. We saw impressive clinical activity in secondary AML (71% CR), AML with MRC (85% CR), and >=60 years (82% CR) which appeared > control.
Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
5/ We found that pomalidomide was able to be safely added at the time of ELR post-induction chemo. MTD = 4 mg x 21 days, most common toxicities (mainly G1-2) = rash, liver function test abnormalities, mucositis and fever.
Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
4/ We hypothesized that immune modulation during a vulnerable time period after induction chemotherapy at ELR may synergize with induction chemotherapy and improve outcomes in AML. To that end, we studied the addition of pomalidomide at early recovery after induction chemo.
Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
3/ So...we asked the question, can we intervene with immune modulation prior to full recovery to counteract this dysfunctional immune state in AML?
Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
2/ We also showed that CD8+ T cells in AML at Dx are exhausted and senescent & persisted in those who did not respond to induction chemo whereas the T cell function was restored in patients who achieved CR. https://insight.jci.org/articles/view/120974 …
Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
1/ The background of this study is that our group previously found that early lymphocyte recovery (~day 21) after induction timed sequential therapy for AML is dominated by an expanded oligoclonal population of Tregs that are immunosuppressive. https://ashpublications.org/blood/article-lookup/doi/10.1182/blood-2010-04-277939 …
Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Excited to start the New Year with
https://www.nature.com/articles/s41375-019-0693-4.pdf …
Phase 1 study of pomalidomide after induction chemo in newly dx AML. Blood, sweat, & tears went into this study over last several years! Thankful for @LLSResearch for funding me!@UNC_Lineberger@hopkinskimmel#leusmPrikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Excellent and impactful paper by
@DrChrisHourigan & colleagues showing the importance of MRD and conditioning intensity in allogeneic transplant for AML. If NGS MRD positive, MAC significantly improves OS and relapse risk compared to RIC. Figure 3 most telling.#leusmhttps://twitter.com/DrChrisHourigan/status/1208131080978518016 …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Best Holiday gift ever!! Thanks
@angienicholsNPpic.twitter.com/r5UVfBU7EH
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Joshua Zeidner proslijedio/la je Tweet
Asciminib was active in heavily pretreated patients with CML who had resistance to or unacceptable side effects from TKIs, including patients in whom ponatinib had failed and those with a T315I mutation. https://nej.md/2E6Ptxk
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
It is rare to witness true practice changing presentations at ASH- oral Azacitidine improves OS and RFS in older AML pts in CR/CRi after intensive induction and consolidation. Favorable-risk was excluded however. Congratulations Andrew Wei & investigators!
#ASH2019#leusmpic.twitter.com/lPGi9QMh8E
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Joshua Zeidner proslijedio/la je Tweet
CONGRESS |
#ASH19 |Another interesting talk,@LeukDocJZ from@UNC_Lineberger presents final results of high dose cytarabine followed by pembrolizumab in R/R AML. Safe with ORR of 46% and CR 38%#leusm#hematologypic.twitter.com/vvLbZ7KS97
Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Checkpoint Inhibitor session in AML- Ivana Gojo presenting data on Aza + Pembro- impressive clinical activity in newly diagnosed elderly AML. Proud to be part of this important study!
@UNC_Lineberger#ASH2019#leusmpic.twitter.com/1UvEXAlX3f
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.